Trial · NCT03505021
Adverse events328
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 328
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Levosimendan | 30 | 326 | 33 |
| other | Fatigue | General disorders | Placebo for Levosimendan | 10 | 166 | 11 |
| other | Oedema peripheral | General disorders | Levosimendan | 26 | 326 | 28 |
| other | Oedema peripheral | General disorders | Placebo for Levosimendan | 12 | 166 | 14 |
| other | Nasopharyngitis | Infections and infestations | Levosimendan | 52 | 326 | 62 |
| other | Nasopharyngitis | Infections and infestations | Placebo for Levosimendan | 26 | 166 | 31 |
| other | Upper respiratory tract infection | Infections and infestations | Levosimendan | 13 | 326 | 16 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo for Levosimendan | 5 | 166 | 5 |
| other | Urinary tract infection | Infections and infestations | Levosimendan | 25 | 326 | 31 |
| other | Urinary tract infection | Infections and infestations | Placebo for Levosimendan | 17 | 166 | 22 |
| other | Heart rate increased | Investigations | Levosimendan | 64 | 326 | 68 |
| other | Heart rate increased | Investigations | Placebo for Levosimendan | 5 | 166 | 5 |
| other | Weight decreased | Investigations | Levosimendan | 26 | 326 | 27 |
| other | Weight decreased | Investigations | Placebo for Levosimendan | 15 | 166 | 15 |
| other | Contusion | Injury, poisoning and procedural complications | Levosimendan | 21 | 326 | 23 |
| other | Contusion | Injury, poisoning and procedural complications | Placebo for Levosimendan | 8 | 166 | 9 |
| other | Fall | Injury, poisoning and procedural complications | Levosimendan | 86 | 326 | 150 |
| other | Fall | Injury, poisoning and procedural complications | Placebo for Levosimendan | 45 | 166 | 100 |
| other | Skin laceration | Injury, poisoning and procedural complications | Levosimendan | 17 | 326 | 20 |
| other | Skin laceration | Injury, poisoning and procedural complications | Placebo for Levosimendan | 12 | 166 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03505021/events?page=2